Kevin Conroy became CEO of Exact Sciences in 2009 and Chairman in 2014, transforming the organization into one of the world’s premier cancer diagnostics companies with more than 6,500 employees.
Mr. Conroy led Exact Sciences through the development, clinical trial, regulatory approval, and commercialization of its noninvasive colorectal cancer screening test, Cologuard®. This culminated with Cologuard becoming the first medical device or diagnostic to receive simultaneous FDA approval and national Medicare coverage. Since 2014, millions of Americans have used Cologuard to screen for colorectal cancer, the second leading cause of cancer death in the United States.
In 2019, Exact Sciences acquired Genomic Health, Inc., uniting two of the industry’s strongest brands, Cologuard and Oncotype DX®. Today, Exact Sciences is working to eradicate cancer and the suffering it causes through tests that detect it earlier and provide guidance for successful treatment.
Before joining Exact Sciences, Mr. Conroy served as CEO and President of Third Wave Technologies, held leadership positions at GE Healthcare, and practiced intellectual property law in private practice. Mr. Conroy currently serves as a director of Epizyme, Inc. and Adaptive Biotechnology Corporation.
Mr. Conroy serves on the board of the American Clinical Laboratory Association and Personalized Medicine Coalition. He is active in the Wisconsin community, serving as a director of the Greater Madison Chamber of Commerce.
A native of Flint, Michigan, Mr. Conroy holds a Bachelor of Science degree in electrical engineering from Michigan State University and earned his Juris Doctorate from the University of Michigan Law School.